Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 242 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Angiogenesis Clear all
Completed Phase 4 Interventional Results available

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

NCT01525550
View directory record Official record
Conditions
Well-differentiated Pancreatic Neuroendocrine Tumor
Interventions
sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Orange, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 27, 2026, 4:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

NCT04941274
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
Abemaciclib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 4:16 AM EDT
Completed Phase 1 Interventional

Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors

NCT01514123
View directory record Official record
Conditions
Neoplasms, Cancer
Interventions
VGX-100, Bevacizumab
Drug
Lead sponsor
Circadian Technologies Ltd.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Santa Monica, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 27, 2026, 4:16 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

NCT00327444
View directory record Official record
Conditions
Ovarian Neoplasms, Ascites
Interventions
aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 1, 2013 · Synced Oct 27, 2026, 4:16 AM EDT
Completed Phase 1 Interventional

A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors

NCT00586092
View directory record Official record
Conditions
Solid Tumors
Interventions
bevacizumab, ABT-510
Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 27, 2026, 4:16 AM EDT
Not listed Phase 2 Interventional

A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment

NCT01509911
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
TL-118, Gemcitabine
Drug
Lead sponsor
Tiltan Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 27, 2026, 4:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue

NCT01150981
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Oct 27, 2026, 4:16 AM EDT
Completed No phase listed Observational

The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins

NCT01341171
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 27, 2026, 4:16 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

NCT04704921
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Interventions
ABBV-RGX-314, Ranibizumab (LUCENTIS®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
89
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 27, 2026, 4:16 AM EDT
Completed Phase 2 Interventional

Efficacy of Hyperbaric Oxygen Therapy in Laryngectomy Patients

NCT00026975
View directory record Official record
Conditions
Laryngeal Cancer
Interventions
Hyperbaric Oxygen
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 27, 2026, 4:16 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma

NCT00383851
View directory record Official record
Conditions
Melanoma
Interventions
ATN-224, Temozolomide
Drug
Lead sponsor
Attenuon
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
17
States / cities
Tucson, Arizona • Encinitas, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2007 · Synced Oct 27, 2026, 4:16 AM EDT
Terminated Phase 1 Interventional

A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors

NCT01137552
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
AMG 780
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 27, 2026, 4:16 AM EDT
Not yet recruiting Phase 2 Interventional

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

NCT05859217
View directory record Official record
Conditions
Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
Interventions
Cabozantinib, Atezolizumab
Drug
Lead sponsor
Jun Zhang, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 27, 2026, 4:16 AM EDT
Completed No phase listed Observational

Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy

NCT01132833
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm, Thromboembolism
Interventions
enzyme-linked immunosorbent assay, laboratory biomarker analysis, medical chart review
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Oct 27, 2026, 4:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab

NCT00932438
View directory record Official record
Conditions
Colon Cancer With Metastases to the Liver
Interventions
LC beads loaded with Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, Bevacizumab
Device · Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Huntsville, Alabama • Sacramento, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 27, 2026, 4:16 AM EDT
Completed Phase 2 Interventional

Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma

NCT00176774
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Irinotecan, 5-Fluorouracil, Leucovorin, Tetrathiomolybdate
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 27, 2026, 4:16 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

NCT05984927
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
NG101 AAV gene therapy
Genetic
Lead sponsor
Elisigen, Inc.
Industry
Eligibility
50 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 4:16 AM EDT
Completed Not applicable Interventional Results available

Effects of Non Contact Low Frequency Ultrasound in Healing Venous Leg Ulcers

NCT01549860
View directory record Official record
Conditions
Venous Insufficiency, Venous Reflux, Lower Extremity Ulcer
Interventions
MIST Therapy
Device
Lead sponsor
Celleration, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 27, 2026, 4:16 AM EDT
Completed Phase 3 Interventional Results available

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

NCT00561470
View directory record Official record
Conditions
Colorectal Neoplasms, Neoplasm Metastasis
Interventions
Placebo, Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
87
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Hot Springs, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 27, 2026, 4:16 AM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 27, 2026, 4:16 AM EDT
Completed Phase 1 Interventional

A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

NCT00619424
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
pazopanib, erlotinib, pemetrexed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Aurora, Colorado • Buffalo, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 27, 2026, 4:16 AM EDT
Completed No phase listed Observational

Collection of Blood, Bone Marrow, Tumor or Tissue Samples

NCT00043615
View directory record Official record
Conditions
Neoplasms, Precancerous Conditions
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 27, 2026, 4:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pathophysiology of Paget's Disease of Bone

NCT02802384
View directory record Official record
Conditions
Paget's Disease of Bone
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 27, 2026, 4:16 AM EDT
Terminated Phase 2 Interventional Results available

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

NCT01441414
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
PF-04856884, Axitinib (AG-013736)
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
28
States / cities
Scottsdale, Arizona • Tucson, Arizona • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 27, 2026, 4:16 AM EDT